ATE423103T1 - Pyrimidin-sulfonamide und ihre verwendung als endothelin-rezeptor-antagonisten - Google Patents
Pyrimidin-sulfonamide und ihre verwendung als endothelin-rezeptor-antagonistenInfo
- Publication number
- ATE423103T1 ATE423103T1 AT03778307T AT03778307T ATE423103T1 AT E423103 T1 ATE423103 T1 AT E423103T1 AT 03778307 T AT03778307 T AT 03778307T AT 03778307 T AT03778307 T AT 03778307T AT E423103 T1 ATE423103 T1 AT E423103T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonists
- endothelin receptor
- preparation
- pharmaceutical compositions
- sulfonamides
- Prior art date
Links
- 229940118365 Endothelin receptor antagonist Drugs 0.000 title abstract 2
- 239000002308 endothelin receptor antagonist Substances 0.000 title abstract 2
- -1 PYRIMIDINE SULFONAMIDES Chemical class 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0213601 | 2002-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE423103T1 true ATE423103T1 (de) | 2009-03-15 |
Family
ID=32405666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03778307T ATE423103T1 (de) | 2002-12-02 | 2003-11-10 | Pyrimidin-sulfonamide und ihre verwendung als endothelin-rezeptor-antagonisten |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7452896B2 (de) |
| EP (1) | EP1569914B1 (de) |
| JP (1) | JP4769460B2 (de) |
| KR (1) | KR101063042B1 (de) |
| CN (1) | CN100379730C (de) |
| AT (1) | ATE423103T1 (de) |
| AU (1) | AU2003285321B2 (de) |
| BR (1) | BR0316724A (de) |
| CA (1) | CA2507334C (de) |
| DE (1) | DE60326263D1 (de) |
| ES (1) | ES2320649T3 (de) |
| IL (1) | IL168836A (de) |
| MX (1) | MXPA05005793A (de) |
| NO (1) | NO20052520L (de) |
| NZ (1) | NZ540937A (de) |
| RU (1) | RU2329255C2 (de) |
| WO (1) | WO2004050640A1 (de) |
| ZA (1) | ZA200505109B (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100739367B1 (ko) | 2004-07-14 | 2007-07-16 | 크리스탈지노믹스(주) | 설파마이드 유도체 및 이를 함유하는 지방대사 촉진용약학적 조성물 |
| TW200628467A (en) * | 2004-11-11 | 2006-08-16 | Actelion Pharmaceuticals Ltd | Novel sulfamides |
| FR2878523B1 (fr) * | 2004-11-30 | 2007-09-14 | Oreal | Nouveaux derives sulfamides et leur utilisation cosmetique |
| US7887824B2 (en) | 2004-11-30 | 2011-02-15 | L'oreal | Sulfamide derivatives and cosmetic use thereof |
| US8168588B2 (en) * | 2005-01-25 | 2012-05-01 | Five Prime Therapeutics, Inc. | Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions |
| US20100100372A1 (en) * | 2007-01-26 | 2010-04-22 | Panasonic Corporation | Stereo encoding device, stereo decoding device, and their method |
| EP2142505A1 (de) * | 2007-04-03 | 2010-01-13 | Pfizer, Inc. | Sulfonamide und pharmazeutische zusammensetzungen davon |
| MX2010001837A (es) * | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| US20110263623A1 (en) * | 2008-08-12 | 2011-10-27 | Cadila Healthcare Limited | Process for preparation of bosentan |
| ES2763176T3 (es) | 2008-08-13 | 2020-05-27 | Actelion Pharmaceuticals Ltd | Composiciones terapéuticas que contienen macitentan |
| CN103724281A (zh) * | 2013-12-03 | 2014-04-16 | 镇江圣安医药有限公司 | N-[5-（4-溴苯基）-6-[2-[（5-溴-2-嘧啶基）氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用 |
| JP7245832B2 (ja) * | 2017-11-21 | 2023-03-24 | ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド | ピリミジンスルファミド系誘導体、その製造方法およびその医薬における使用 |
| CN108997223B (zh) * | 2018-08-09 | 2020-06-30 | 浙江先锋科技股份有限公司 | 5-(4-溴苯基)-4，6-二氯嘧啶的制备方法 |
| CN109232546B (zh) | 2018-09-25 | 2020-09-04 | 中国人民解放军总医院 | 一种嘧啶磺酰胺类衍生物的医药用途 |
| RU2763899C1 (ru) * | 2021-03-26 | 2022-01-11 | федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации | Натриевая соль 4-{ 2-[2-(4-гидрокси-3-метоксифенил)-винил]-6-этил-4-оксо-5-фенил-4H-пиримидин-1-ил} -бензсульфамида, обладающая противоопухолевым действием |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1549494A (de) | 1967-10-31 | 1968-12-13 | ||
| DE2801584A1 (de) | 1978-01-14 | 1979-07-19 | Bayer Ag | Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide |
| RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| TW394761B (en) | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
| IL111959A (en) | 1993-12-17 | 2000-07-16 | Tanabe Seiyaku Co | N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them |
| TW313568B (de) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| US5739333A (en) | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
| JP3013752B2 (ja) * | 1995-05-16 | 2000-02-28 | 田辺製薬株式会社 | スルホンアミド誘導体 |
| WO1997022595A1 (en) | 1995-12-20 | 1997-06-26 | Yamanouchi Pharmaceutical Co., Ltd. | Arylethenesulfonamide derivatives and drug composition containing the same |
| TWI284642B (en) * | 1999-01-18 | 2007-08-01 | Hoffmann La Roche | Novel heterocyclic sulfonamides |
| WO2002053557A1 (en) | 2000-12-18 | 2002-07-11 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
-
2003
- 2003-11-10 EP EP03778307A patent/EP1569914B1/de not_active Expired - Lifetime
- 2003-11-10 BR BR0316724-0A patent/BR0316724A/pt not_active IP Right Cessation
- 2003-11-10 MX MXPA05005793A patent/MXPA05005793A/es active IP Right Grant
- 2003-11-10 CA CA2507334A patent/CA2507334C/en not_active Expired - Fee Related
- 2003-11-10 CN CNB2003801034698A patent/CN100379730C/zh not_active Expired - Fee Related
- 2003-11-10 WO PCT/EP2003/012502 patent/WO2004050640A1/en not_active Ceased
- 2003-11-10 AT AT03778307T patent/ATE423103T1/de active
- 2003-11-10 KR KR1020057008632A patent/KR101063042B1/ko not_active Expired - Fee Related
- 2003-11-10 RU RU2005120769/04A patent/RU2329255C2/ru not_active IP Right Cessation
- 2003-11-10 NZ NZ540937A patent/NZ540937A/en unknown
- 2003-11-10 ES ES03778307T patent/ES2320649T3/es not_active Expired - Lifetime
- 2003-11-10 US US10/537,400 patent/US7452896B2/en not_active Expired - Fee Related
- 2003-11-10 AU AU2003285321A patent/AU2003285321B2/en not_active Ceased
- 2003-11-10 JP JP2004556119A patent/JP4769460B2/ja not_active Expired - Fee Related
- 2003-11-10 DE DE60326263T patent/DE60326263D1/de not_active Expired - Lifetime
-
2005
- 2005-05-25 NO NO20052520A patent/NO20052520L/no not_active Application Discontinuation
- 2005-05-26 IL IL168836A patent/IL168836A/en active IP Right Grant
- 2005-06-23 ZA ZA200505109A patent/ZA200505109B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003285321B2 (en) | 2010-04-08 |
| ES2320649T3 (es) | 2009-05-27 |
| CN100379730C (zh) | 2008-04-09 |
| US7452896B2 (en) | 2008-11-18 |
| JP2006509775A (ja) | 2006-03-23 |
| AU2003285321A1 (en) | 2004-06-23 |
| NO20052520D0 (no) | 2005-05-25 |
| RU2005120769A (ru) | 2006-02-27 |
| CA2507334A1 (en) | 2004-06-17 |
| RU2329255C2 (ru) | 2008-07-20 |
| US20070167472A1 (en) | 2007-07-19 |
| CA2507334C (en) | 2013-05-07 |
| MXPA05005793A (es) | 2005-08-16 |
| JP4769460B2 (ja) | 2011-09-07 |
| NZ540937A (en) | 2008-06-30 |
| IL168836A (en) | 2010-12-30 |
| CN1711248A (zh) | 2005-12-21 |
| KR20050086625A (ko) | 2005-08-30 |
| EP1569914A1 (de) | 2005-09-07 |
| BR0316724A (pt) | 2005-10-18 |
| NO20052520L (no) | 2005-06-27 |
| DE60326263D1 (de) | 2009-04-02 |
| KR101063042B1 (ko) | 2011-09-07 |
| EP1569914B1 (de) | 2009-02-18 |
| WO2004050640A1 (en) | 2004-06-17 |
| ZA200505109B (en) | 2007-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20051102L (no) | Sulfonylamino-eddiksyre-derivater | |
| ATE435210T1 (de) | Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten | |
| ATE312090T1 (de) | 4-(piperidyl- und pyrrolidyl-alkyl-ureido)- chinoline als urotensin ii rezeptor antagonisten | |
| MXPA03004780A (es) | Nuevas sulfamidas. | |
| ATE286500T1 (de) | 1,2,3,4-tetrahydroisochinolin-derivate | |
| NO20034230D0 (no) | 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister | |
| NO20032905D0 (no) | Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister | |
| DE60326263D1 (de) | Pyrimidin-sulfonamide und ihre verwendung als endothelin-rezeptor-antagonisten | |
| DE602004011204D1 (de) | Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten. | |
| MXPA03010158A (es) | Sulfonamidas. | |
| DE60101372D1 (de) | Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität | |
| MXPA04001252A (es) | Nuevos heterociclos benzo-fusionados como antagonistas de endotelina. | |
| WO2005030209A8 (en) | Pyridine derivatives and use thereof as urotensin ii antagonists | |
| WO2002024665A8 (en) | Arylalkane-sulfonamides having endothelin-antagonist activity | |
| MXPA03000430A (es) | Nuevas arileteno-sulfonamidas. | |
| ATE386525T1 (de) | 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel | |
| ATE462703T1 (de) | Bicyclononen-derivate als renin-inhibitoren | |
| TW200628467A (en) | Novel sulfamides | |
| ATE338045T1 (de) | Substituierte pyrido(1,2-a)pyrimidine und ihre verwendung als nos-inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1569914 Country of ref document: EP |